沃索里提德,一种奇迹药物,覆盖了无形质形成症的未满足需求:监管更新
Simran1, Kirthiga Devi S S1, Sabanis Chetan Dushantrao1
1Department of Regulatory Affairs, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
Intractable & rare diseases research
|November 29, 2023
概括
沃克索戈 (vosoritide) 是一种用于治疗罕见的矮形态 - - 无粒细胞形成症的新药. 它获得了美国FDA和EMA的批准,这是治疗这种疾病的里程碑,尽管已知副作用.
科学领域:
- 医学科学 医学科学 医学科学
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 小矮症,主要是由无形质形成症引起的,显著影响患者的社会福祉.
- 骨质疏松症是一种导致不成比例的矮身的遗传疾病.
研究的目的:
- 对沃索里提德 (Voxzogo) 的孤儿药批准程序进行审查.
- 为了突出vosoritide作为治疗无粒细胞增生症的重要性.
主要方法:
- 对vosoritide的监管文件和临床试验数据的审查.
- 美国食品和药物管理局 (FDA) 和欧洲药品管理局 (EMA) 批准途径的分析.
主要成果:
- 沃索里提德 (Voxzogo) 获得了美国FDA的加速批准,用于治疗无形质,符合罕见儿科疾病的标准.
- 欧洲药品署 (EMA) 也通过集中程序批准了沃索里提德.
- 已知降低血压的不良事件被药物的益处所抵消.
结论:
- 沃索里提德代表了无形细胞增生症治疗的重大进展.
- 批准过程强调了解决罕见儿科疾病中未得到满足的医疗需求的重要性.
- 沃索里提德的旅程突出了孤儿药物开发和批准的里程碑.
相关概念视频
Prescription, Nonprescription and Orphan Drugs
740
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
740
Cystic Fibrosis: Management
172
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
172
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Preclinical Development: Overview
4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
162
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
162
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
170
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
170


